Clinical Trial Update: A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response [Phase 3]

View source ↗

Summary

Phase 3 study assessing the combination of Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin) in patients with chronic hepatitis C genotype 2 or 3 w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2013-06-24